Loading clinical trials...
Loading clinical trials...
Background: Endocrine glands give off hormones. Researchers want to learn more about the disorders that affect these glands in children. These disorders might be caused by changes in genes. Genes contain DNA, which is the blueprint of how a cell works. Researchers want to identify the genes involved in endocrine and metabolic disorders. This might help develop new ways to diagnose and treat the disorders. Objective: To study the inheritance of endocrine or metabolism disorders. Eligibility: Children ages 3month-18 with known or suspected endocrine or metabolism disorders. Family members ages 3months-100. They may participate in the DNA part of the study. Design: Participants will be screened with a review of their medical records. Their parents or guardians will allow the records to be released. Participants will have a clinic visit. This may include a physical exam and medical history. Parents or guardians will give their consent for the study. Participants may have tests, surgery, or other procedures to help diagnose or treat their condition. These could include: Blood, urine, and saliva tests Growth hormone test Pituitary and adrenal function tests Picture of chromosomes Imaging tests. These may include X-ray, ultrasound, scans, or a skeletal survey. Genetic tests Sleep study Medical photographs If surgery is done, a tissue sample will be taken. Participants may have follow-up visits for diagnosis and treatment. Participating relatives will have one visit. This will include medical history and blood and saliva tests. The blood and saliva will be used for DNA testing.
Study Description: This protocol is designed to allow endocrine-related evaluations of children with known or suspected endocrine or metabolic disorders. Children with endocrine or metabolic-related condition(s) who may or may not be eligible for a specific NICHD research protocol, may be evaluated under the auspices of this protocol. Standard clinically indicated laboratory or radiological studies may be performed to confirm a diagnosis or to aid in the management of the patient. In some cases, the child participant may receive medical or surgical treatment for their disorder at the National Institutes of Health (NIH) Clinical Center (CC) according to current clinical practice. Family members of children evaluated on this protocol (who have informative meiotic inheritance relationships to the proband or index case) may be enrolled in the genetic/DNA testing part of the protocol. Objectives: Primary Objective: -Comprehensive evaluation of pediatric endocrine diseases and conditions as well as track natural progress of the development of such conditions in diverse population of pediatric subjects with a known or suspected endocrine or metabolic disorder. Secondary Objective: -Samples for molecular genetic or WES testing Endpoints: Primary Endpoint: Appraisal of number and diversity of endocrine related diagnosis of patients evaluated on this protocol. Secondary Endpoints: -Number of samples for molecular genetic or WES testing.
Age
0 - 100 years
Sex
ALL
Healthy Volunteers
No
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
July 12, 2016
Primary Completion Date
December 31, 2030
Completion Date
December 31, 2030
Last Updated
September 24, 2025
15,000
ESTIMATED participants
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT06662045
NCT07203495
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions